Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics (all randomised analysis set)

From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD

 EnsifentrinePlacebo (N = 80)
0.75 mg (N = 82)1.5 mg (N = 81)3 mg (N = 82)6 mg (N = 80)
Age, years63.6 (7.05)63.4 (6.40)62.5 (6.51)62.9 (6.73)63.5 (6.44)
Sex, n (%)
 Male56 (68)46 (57)45 (55)48 (60)50 (63)
 Female26 (32)35 (43)37 (45)32 (40)30 (38)
Race, n (%)
 White82 (100)81 (100)82 (100)80 (100)80 (100)
Post-bronchodilator FEV1
 L1.67 (0.464)1.60 (0.466)1.62 (0.441)1.63 (0.474)1.69 (0.493)
 % predicted56.0 (10.34)56.0 (9.83)55.6 (10.18)55.3 (9.47)56.0 (9.89)
FEV1 reversibility, %10.4 (10.13)11.0 (12.32)12.9 (13.53)12.3 (11.14)11.7 (10.60)
Smoking status, n (%)
 Current50 (61)40 (49)47 (57)42 (53)43 (54)
 Ex32 (39)41 (51)35 (43)38 (48)37 (46)
Smoking history, pack-years44.7 (21.27)43.7 (21.98)41.8 (19.05)37.3 (16.75)43.3 (20.21)
Chronic bronchitis, n (%)48 (59)43 (53)56 (68)58 (73)46 (58)
SGRQ-C49.9 (17.36)43.4 (17.06)42.1 (18.78)44.1 (15.02)42.3 (17.07)
BDI5.9 (1.44)6.4 (1.81)6.4 (1.43)6.4 (1.16)6.4 (1.38)
MRC2.8 (0.82)2.5 (0.79)2.5 (0.79)2.6 (0.73)2.5 (0.75)
MRC score, n (%)
  < 24 (5)8 (10)6 (7)4 (5)4 (5)
  ≥ 278 (95)73 (90)76 (93)76 (95)76 (95)
Rescue medication, puffs per daya1.5 (1.80)1.5 (1.84)1.9 (2.14)1.9 (2.13)1.5 (1.88)
E-RS:COPD™b13.6 (6.77)12.3 (6.05)12.0 (6.03)12.2 (6.29)11.5 (6.23)
Concomitant ICS use, n (%)33 (40)36 (44)29 (35)32 (40)28 (35)
  1. Data are mean (standard deviation) unless specified otherwise
  2. aAvailable baseline data from 81, 81, 82, 80 and 79 patients, respectively
  3. bAvailable baseline data from 75, 75, 77, 77 and 77, respectively
  4. Abbreviations: FEV1 forced expiratory volume in 1 s, SGRQ-C St George’s Respiratory Questionnaire – COPD Specific, BDI Baseline Dyspnoea Index, MRC Medical Research Council dyspnoea scale, E-RS:COPD™ Evaluating Respiratory Symptoms in COPD questionnaire, COPD chronic obstructive pulmonary disease, ICS inhaled corticosteroid